Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 28%
Buy 56%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie is poised for strong performance, supported by a diverse portfolio that includes pharmaceuticals, immunology, and aesthetics products. Recent acquisitions, such as Allergan, Cerevel, and ImmunoGen, have supplemented the company's portfolio and provide potential for future growth. The company's 1Q 2026 earnings were inline, with revenue and earnings in line with AbbVie's guidance. Guggenheim has raised revenue estimates, primarily driven by increased sales estimates for Rinvoq and Skyrizi, and has increased its DCF-derived price target on ABBV shares to $249/share. While there may be concerns about Skyrizi and Rinvoq's longer-term growth, AbbVie's strong performance and potential pipeline developments suggest high single-digit topline growth through the decade.

Bears say

AbbVie is a pharmaceutical company that reported solid 1Q 2026 results with total net revenues of $15.00Bn and adjusted EPS of $2.65, both of which exceeded estimates. The company raised their FY 2026 revenue and EPS guidance, and showed promising data for their pipeline programs in multiple therapeutic areas. However, there are downside risks, such as potential pricing and competition risks for key products, and the potential impact of tariffs and taxes on the company's low tax rate. Additionally, the forecasted growth of their aesthetics franchise has been lowered.

AbbVie (ABBV) has been analyzed by 18 analysts, with a consensus rating of Buy. 28% of analysts recommend a Strong Buy, 56% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 18 analysts, AbbVie (ABBV) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $256.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $256.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.